Group 1 - The core viewpoint of the article highlights that KenSheng Technology-B (09877) has seen a significant stock increase of over 8%, reaching 9.2 HKD with a trading volume of 1.0444 million HKD [1] - The company announced that its transcatheter aortic valve replacement system, Ken-Valve, and transcatheter tricuspid valve replacement system, LuX-ValvePlus, have recently received registration approval from the New Zealand Medicines and Medical Devices Safety Authority [1] - The approval is expected to accelerate the global commercialization process of these two key products, aligning with the company's long-term strategic goals [1] Group 2 - The announcement emphasizes that the products have gained widespread market recognition due to their design advantages, ongoing clinical trials, and continuous promotion of therapies [1] - The company is actively pushing for the commercialization of Ken-Valve and LuX-ValvePlus in New Zealand following the recent regulatory approval [1]
港股异动 健世科技-B(09877)涨超8% 两款核心治疗心脏瓣膜疾病产品获新西兰注册批准